Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 14;43(11):2956–2966. doi: 10.1038/s41401-022-00905-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society 2022, corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 4 — a–c Colony formation ability was evaluated using a colony formation assay. H157 and HCC827 cells were treated with osimertinib in complete medium for 10–14 days. The colonies were counted and imaged. d Stable H157-Lac-Z and c-FLIP cells were treated with osimertinib. Cell viability was evaluated by a CCK8 assay. e A CCK8 assay was used to evaluate the effect of osimertinib on the growth of negative control and FoxM1 knockout H157 cells. f Immunoblotting showed the protein levels of FoxM1 and c-FLIP in PC9 and PC9/OR cells. g The viability of PC9 and PC9/OR cells upon osimertinib treatment was evaluated by a CCK8 assay. h The viability of PC9 and PC9/OR cells upon TST treatment was evaluated by a CCK8 assay. The data presented are from three independent experiments (*P < 0.05 vs. the control group; **P < 0.01 vs. the control group).